Alicia A Martinez

Address:

602 NW 20 Ave, Miami, FL 33125

VIN:

YV4982DL7A2082070

Make:

VOLVO

Model:

XC60

Year:

2010

Address:

5060 Westwood Lk Dr, Miami, FL 33165

VIN:

3A8FY48B78T115315

Make:

CHRYSLER

Model:

PT CRUISER

Year:

2008

US Patent:

D522054, May 30, 2006

Filed:

Mar 29, 2004

Appl. No.:

29/202196

Inventors:

Alicia Kim Martinez - Queens Village NY, US

International Classification:

1904

US Classification:

D19 26

US Patent:

20210000946, Jan 7, 2021

Filed:

Mar 4, 2019

Appl. No.:

16/977290

Inventors:

- New York NY, US
Alicia Hurtado Martinez - New York NY, US
Christine Pampeno - New York NY, US
Iris Scherwitzl - New York NY, US

International Classification:

A61K 39/39
C12N 7/00
C07K 14/705
C07K 14/47
A61K 39/00
A61P 35/00

Abstract:

Provided are polynucleotides and viral vectors, particularly, vectors such as Sindbis viral vectors, which encode an immune checkpoint protein, or a ligand binding portion of the checkpoint protein, or an immune checkpoint protein or ligand binding portion thereof fused to one or more immunoglobulin (Ig) domains, e.g., an Ig hinge region and an Ig heavy chain constant domain. Methods of treating a mammalian subject having a cancer or tumor are provided, in which the viral vectors, e.g., a Sindbis virus vector, encoding the immune checkpoint protein, a ligand binding portion thereof, or a checkpoint protein fusion protein as described, are administered to the subject, resulting in an anti-cancer or anti-tumor immune response, significant reduction in tumor growth in the treated subject and increased survivability.

US Patent:

20200377598, Dec 3, 2020

Filed:

Mar 5, 2018

Appl. No.:

16/489769

Inventors:

- New York NY, US
Alicia Hurtado Martinez - New York NY, US
Christine Pampeno - New York NY, US
Iris Scherwitzl - Hoboken NJ, US

International Classification:

C07K 16/28
C07K 14/705
C12N 15/86
A61P 35/00

Abstract:

Provided are polynucleotides and viral vectors, e.g., alphavins or Sindbis viral vectors, encoding multiple, e.g., two or more, epitopes of at least one tumor associated antigen, in which each epitope is separated by a processing or enzyme cleavage site. The encoded epitopes may be the same or different. Also provided are polynucleotides and viral vectors, particularly, alphavirus or Sindbis viral vectors, encoding an immune checkpoint protein, or a ligand binding portion thereof. The immune checkpoint protein or ligand binding portion thereof may be fused to immunoglobulin domains, e.g., an Ig hinge domain and an Ig heavy chain constant domain. Methods of treating subjects having a cancer or tumor, e.g., a TAA-expressing tumor, with the described viral vectors are provided. Treatment of subjects with the vectors, the checkpoint inhibitor molecules and/or other immunomodulatory components, generate an anti-cancer or anti-tumor immune response resulting in increased survivability of tumored subjects and epitope spreading.

US Patent:

20180000912, Jan 4, 2018

Filed:

Mar 3, 2017

Appl. No.:

15/449641

Inventors:

- New York NY, US
Christine Pampeno - New York NY, US
Alicia Hurtado Martinez - New York NY, US

International Classification:

A61K 39/00
C12N 9/12
C07K 14/47
C12N 7/00
C07K 14/005

Abstract:

Provided are polynucleotides and viral vectors, particularly, alphavirus vectors such as Sindbis viral vectors, which encode multiple, e.g., two or more, epitopes of at least one tumor associated antigen in which each epitope is separated by a processing or enzyme cleavage site. The multiple epitopes of the two or more tumor associated antigens encoded by the described polynucleotides and viral vectors may be the same or different. Methods of treating mammalian subjects having a cancer or tumor expressing the tumor associated antigen epitopes are provided, in which the viral vectors encoding the multiple epitopes, as well as other immunostimulatory or immunomodulatory components, generate an anti-cancer or anti-tumor immune response in which high levels of effector T cells increase the survivability of tumored mammalian subjects and result in epitope spreading, thus providing a further enhancement of the immune response.